Literature DB >> 10842611

Cochlear effects of mesna application into the middle ear.

V Vincenti1, M Mondain, E Pasanisi, F Piazza, J L Puel, S Bacciu, N Quaranta, A Uziel, C Zini.   

Abstract

Mesna (sodium 2-mercapto-ethane sulphonate) belongs to a class of thiol compounds that produce mucolysis by disrupting the disulphide bonds of the mucus polypeptide chains. The registered indications of mesna include the treatment of pathologies of the respiratory tract and, in oncology, the prevention of toxic lesions of the urinary tract by antineoplastic agents. In the E.N.T. Clinic of the University of Parma, it has been found that mesna can be used to facilitate the dissection of the various tissue layers in any surgical procedure. One of these indications is surgical treatment of cholesteatoma, which is mainly composed by keratin, a protein rich is disulphide bonds that are easily disrupted by mesna. The aim of this study was to evaluate the toxicity of mesna application into the middle ear on the cochlear anatomy and physiology. Three groups of guinea pigs were used as subjects. Mesna solution (10 or 20%) was applied in one ear, while the opposite ear received a placebo (saline solution). Toxicity of mesna was assessed by means of transmission electron microscopy (TEM), scanning electron microscopy (SEM), and auditory brain-stem response (ABR). TEM and SEM did not show any toxic effect on cochlear morphology. There were no differences in ABR thresholds and wave III amplitude and latency between mesna-treated and control ears.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10842611     DOI: 10.1111/j.1749-6632.1999.tb08659.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Electrophysiological and Histopathological Evaluation of Effects of Sodium-2 Mercaptoethanesulfonate Used for Middle Ear Surgery on Facial Nerve Functions.

Authors:  Oğuz Kadir Eğilmez; Numan Kökten; Mustafa Baran; M Tayyar Kalcıoğlu; Işın Doğan Ekici; Muhammet Tekin
Journal:  J Int Adv Otol       Date:  2018-08       Impact factor: 1.017

2.  Failed back surgery syndrome: a new strategy by the epidural injection of MESNA.

Authors:  M Carassiti; A Di Martino; A Centonze; C C Quattrocchi; A Caldaria; F Agrò; V Denaro
Journal:  Musculoskelet Surg       Date:  2017-11-02

3.  Cochlear implantation in chronic otitis media and previous middle ear surgery: 20 years of experience.

Authors:  V Vincenti; E Pasanisi; A Bacciu; S Bacciu; C Zini
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-08       Impact factor: 2.124

4.  After myringotomy, can topical Mesna application be an alternative method to ventilation tube application?

Authors:  Rifat Karli; Fatih Ilkaya; Arzu Karli; Emre Gunbey; Harun Kucuk; Hasan Guzel; Emre Ayhan
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-08       Impact factor: 2.503

5.  Effectiveness of a mucolythic agent as a local adjuvant in revision lumbar spine surgery.

Authors:  Vincenzo Denaro; Alberto Di Martino; Umile Giuseppe Longo; Vincenzo Costa; Rocco Papalia; Francisco Forriol; Luca Denaro
Journal:  Eur Spine J       Date:  2008-10-07       Impact factor: 3.134

6.  The effects of sodium-2-mercaptoethanesulfonate application on the neural and neurovascular tissues: An experimental animal study.

Authors:  Ayca Ant; Recep Karamert; Gamze Kulduk; Özgür Ekinci; Hakan Tutar; Nebil Göksu
Journal:  Surg Neurol Int       Date:  2015-09-18

7.  Screw migration and oesophageal perforation after surgery for osteosarcoma of the cervical spine.

Authors:  Luca Denaro; Umile Giuseppe Longo; Alberto Corrado Di Martino; Nicola Maffulli; Vincenzo Denaro
Journal:  BMC Musculoskelet Disord       Date:  2017-12-29       Impact factor: 2.362

8.  Inhibitory effect of mesna and 5-fluorouracil on propylene glycol-induced cholesteatoma in rats.

Authors:  Numan Kokten; Ozan Tuysuz; Tulay Zenginkinet; Fatih Mehmet Hanege; Mahmut Tayyar Kalcioglu
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-10       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.